key: cord-0933568-7ykr60ax
authors: Bardazzi, Federico; Abbenante, Diego; Filippi, Federica; Sacchelli, Lidia; Loi, Camilla
title: The initial experience of COVID‐19 vaccination in autoimmune blistering diseases patients from a reference care center in Italy
date: 2021-07-14
journal: Dermatol Ther
DOI: 10.1111/dth.15057
sha: 00792b7776d4dc846d5919d807d69d28e0ac7e7d
doc_id: 933568
cord_uid: 7ykr60ax

nan

The initial experience of COVID-19 vaccination in autoimmune blistering diseases patients from a reference care center in Italy Dear Editor, Vaccines to prevent SARS-CoV-2 infection are considered the most promising approach in controlling the pandemic and COVID-19 vaccine development is proceeding at an unprecedented pace.

Because of limited vaccine supplies, each state has provided strategic guidelines and recommendations for vaccine allocation approaches that maximize the individual and societal benefits of vaccination. These recommendations generally propose initially vaccinating those with increased risk factors for a severe course, as well as those employed in critical sectors.

Regarding patients suffering from autoimmune blistering diseases (AIBD), it has not yet been established whether they have a greater risk of be infected with SARS-CoV-2 compared with healthy individuals. 1 However, because of the immunosuppressive background of the autoimmune disorder itself and the immunosuppressive drugs used in the treatment of these diseases, it is reasonable to think that these patients have a higher susceptibility to bacterial and viral infections. 2 In conclusion, we are convinced that while the immunogenicity and efficacy of COVID-19 vaccines remain uncertain in immunocompromised patients, the potential benefit from vaccination likely outweighs any risk. Although further studies will be needed to define the efficacy of SARS-Cov2 vaccines in AIBD patients undergoing immunosuppressant treatments, in our opinion their immunization is highly recommendable. In the lack of official guidelines, we currently suggest evaluating case-by-case the risk-benefit ratio of maintaining the ongoing immunosuppressive therapy before performing the vaccine.

Federico Bardazzi and Diego Abbenante contributed equally to this study.

COVID-19 outbreak and autoimmune bullous diseases: a systematic review of published cases

Guidance from the EADV Task Force Autoimmune Blistering Diseases during the COVID-19 pandemic. The EADV Task force Autoimmune Blistering Diseases supports patients and their families during this difficult period of COVID-19 pandemic and provides the following advices

Pemphigus and COVID-19: critical overview of management with a focus on treatment choice

Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV)

Three case reports of post immunization and post viral bullous Pemphigoid: looking for the right trigger

Pemphigus trigger factors: special focus on pemphigus vulgaris and pemphigus foliaceus

American College of Rheumatology Guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases-version 1